Loading...
| A03787 | Pages: NA | Dec 2021 | 4792 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Rna Interference (rnai) Drug Delivery Market
Request Now !RNA Interference (RNAi) is a biological process in which RNA molecules inhibit the gene expression. Study of RNAi helps in the analysis of gene functions in eukaryotic organisms.
The global RNAi drug delivery market is driven by several factors such as increasing research activities in the field of RNA therapeutics, growing number of academic research institutes, and increasing prevalence of chronic disorders such as cardiac abnormalities and cancer. However, high costs of research and threat of failure will restrain the market growth. Increasing research in the field of nanotechnology will provide opportunities for the market growth.
The report segments the global RNAi drug delivery market based on the type of drug delivery technology, application, and region. Based on type of drug delivery technology, it is segmented into nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology, and aptamer drug delivery technology. Based on application it is segmented into infectious diseases, cardiology, oncology, neurology, ophthalmology, and metabolic disorders. Geographically, it has been analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Key players that operate in the market include Tekmira Pharmaceuticals Corp., Alnylam Pharmaceuticals Inc., Merck & Co. Inc., Isis Pharmaceuticals, Inc., Access Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Marina Biotech Inc., RXi Pharmaceuticals Corp., and Quark Pharmaceuticals Inc.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 RNAI DRUG DELIVERY MARKET, BY DRUG DELIVERY TECHNOLOGY
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. NANOPARTICLE DRUG DELIVERY TECHNOLOGY
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. PULMONARY DRUG DELIVERY TECHNOLOGY
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. NUCLIEC ACID DRUG DELIVERY TECHNOLOGY
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. APTAMER DRUG DELIVERY TECHNOLOGY
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5 RNAI DRUG DELIVERY MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. INFECTIOUS DISEASES
5.2.1. Market size and forecast
5.3. CARDIOLOGY
5.3.1. Market size and forecast
5.4. ONCOLOGY
5.4.1. Market size and forecast
5.5. NEUROLOGY
5.5.1. Market size and forecast
5.6. OPTHALMOLOGY
5.6.1. Market size and forecast
5.7. METABOLIC DISORDERS
5.7.1. Market size and forecast
CHAPTER 6 RNAI DRUG DELIVERY MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America RNAi drug delivery market by drug delivery technology
6.2.5. North America RNAi drug delivery market by application
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe RNAi drug delivery market by drug delivery technology
6.3.5. Europe RNAi drug delivery market by application
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific RNAi drug delivery market by drug delivery technology
6.4.5. Asia-Pacific RNAi drug delivery market by application
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast
6.5.4. LAMEA RNAi drug delivery market by drug delivery technology
6.5.5. LAMEA RNAi drug delivery market by application
CHAPTER 7 COMPANY PROFILES
7.1. TEKMIRA PHARMACEUTICALS CORP
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. ALNYLAM PHARMACEUTICALS INC.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. MERCK & CO. INC.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. ISIS PHARMACEUTICALS, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. ACCESS PHARMACEUTICALS INC.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. DICERNA PHARMACEUTICALS INC.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. CALONDO PHARMACEUTICALS INC.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. MARINA BIOTECH INC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. RXI PHARMACEUTICALS CORP
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. QUARK PHARMACEUTICALS INC.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
